Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

Recruiting

• Conditions: HER2-positive Breast Cancer

• Registration Number: NCT06711055
• Lead Sponsor: Shu Wang

Brief Summary

Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk of recurrence and metastasis. HER2 targeted drugs has greatly improved the prognosis and survival of such patients. At present, for HER2 positive breast cancer patients with negative lymph nodes, chemotherapy drugs combined with trastuzumab is the current standard treatment scheme, and in most cases, chemotherapy uses a combination of two drugs, while the main beneficiaries of the trastuzumab and paltuzumab are concentrated in the group of patients with positive lymph nodes. Can targeted therapy be used to reduce the progression of chemotherapy and further achieve efficient and low toxicity strategies. To explore the efficacy and safety of adjuvant therapy of taxane chemotherapy combined with trastuzumab targeting therapy for low-risk HER2 positive and lymph node negative early breast cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01-01
• Status Verified: 2024-11
• Study First Submitted: 2024-11-26
• Study First Submitted QC: 2024-11-26
• Last Update Submitted: 2024-11-26
• Study First Posted: 2024-12-02
• Last Update Posted: 2024-12-02
• Primary Completion: 2031-12-31
• Study Completion: 2031-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 285

Inclusion Criteria

• 1. Treatment in Peking University People's Hospital for radical resection of breast cancer and had hospitalization records;
• 2. Postoperative pathology confirmed invasive breast cancer, and the pathological stage was T1a-b (T ≤ 1cm), N0, HER2 positive, with high-risk factors (G3, or hormone receptor negative); Or the pathological stage is T1c (1cm < T ≤ 2cm), N0, and there are no high-risk factors (G1/G2, hormone receptor positive);
• 3)Signed an agreement to participate in the PKUPH Breast Disease Cohort study at Peking University People's Hospital.

Exclusion Criteria

• 1. Lack of clinical pathological data (such as imaging data, pathological data);
• 2. Preoperative neoadjuvant therapy;
• 3. Patients with metastatic breast cancer or bilateral breast cancer;
• 4. Failed to undergo curative surgery.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
invasive disease free survival	5 years	The time from enrollment to the first occurrence of the following events defined as failure: local recurrence of ipsilateral invasive breast cancer, contralateral invasive breast cancer, distant recurrence or death from any cause.

Secondary Outcome Measures

Name	Time	Method
disease free survival	5 years	The time from enrollment to the first occurrence of the following events defined as failure, including ipsilateral local recurrence, contralateral breast cancer, distant recurrence or death from any cause.
distant disease free survival	5 years	The time from enrollment in the study to the occurrence of distant recurrence and metastasis.
breast cancer specific survival	5 years	Time from enrollment to death due to breast cancer. Time from enrollment to death due to breast cancer.
overall survival	5 years	The time from enrollment in the study to death caused by any reason

Trial Locations

Locations (1)

Peking University People's Hospital; 🇨🇳 Beijing, Beijing, China